|
|
|
|
| LEADER |
01532nam a2200289 u 4500 |
| 001 |
EB001840040 |
| 003 |
EBX01000000000000001004029 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
180702 r ||| eng |
| 245 |
0 |
0 |
|a Anticoagulation monitoring and reversal strategies for dabigatran, rivaroxaban, and apixaban
|h Elektronische Ressource
|b a review of clinical effectiveness
|c prepared by Canadian Agency for Drugs and Technologies in Health
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c April 2012, 2012
|
| 300 |
|
|
|a 1 PDF file (15 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Rivaroxaban
|
| 653 |
|
|
|a Antithrombins / adverse effects
|
| 653 |
|
|
|a Hemorrhage / therapy
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Dabigatran
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH therapeutic review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK356439
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The purpose of this report is to review the clinical effectiveness and cost of strategies to identify over-anticoagulation states and strategies to treat bleeding associated with the use of dabigatran, rivaroxaban, and apixaban, with the broader aim to help inform future listing recommendations and decisions, as well as clinical practice
|